(Q40257223)

18 September 2017

title

Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization (English)

1 reference

18 September 2017

main subject

coronary artery disease

1 reference

Brian G Sandhoff

1

1 reference

18 September 2017

Leslie K Nies

2

1 reference

18 September 2017

Kari L Olson

3

1 reference

18 September 2017

James D Nash

4

1 reference

18 September 2017

Jon R Rasmussen

5

1 reference

18 September 2017

John A Merenich

6

1 reference

18 September 2017

publication date

1 January 2007

1 reference

American Journal of Health-System Pharmacy

18 September 2017

published in

1 reference

18 September 2017

volume

64

1 reference

18 September 2017

issue

1

1 reference

18 September 2017

page(s)

77-84

1 reference

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Treatment of hypertension in adults with diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Cholesterol risk management: a systematic examination of the gap from evidence to practice

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Goal attainment and maintenance of serum cholesterol level in a pharmacist-coordinated lipid clinic.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Lipid lowering in a multidisciplinary clinic compared with primary physician management

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Randomised trials of secondary prevention programmes in coronary heart disease: systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Side effects of statins: hepatitis versus "transaminitis"-myositis versus "CPKitis".

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Criteria of drug-induced liver disorders. Report of an international consensus meeting

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Standards of medical care for patients with diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060022

31 March 2020

Identifiers

DOI

10.2146/AJHP060022

1 reference

18 September 2017

1 reference